From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
(2R)-2-[(1S)- 6,7-dimethoxy- 1-{2-[4-(trifluoromethyl)phenyl]ethyl}- 3,4-dihydroisoquinolin-2(1H)-yl]- N-methyl- 2-phenylacetamide
Clinical data
Routes of
Pharmacokinetic data
Metabolism Hepatic
CAS Number 871224-64-5
ATC code none
PubChem CID 23727689
Chemical data
Formula C29H32ClF3N2O3
Molar mass 512.6 g/mol (free base)[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Almorexant (INN, codenamed ACT-078573) is a competitive receptor antagonist of the OX1 and OX2 orexin receptors, being developed by the pharmaceutical company Actelion for the treatment of primary insomnia. It has completed a Phase III clinical trial in November 2009.[1]

Mechanism of action

Almorexant is a competitive, dual OX1 and OX2 receptor antagonist and selectively inhibits the functional consequences of OX1 and OX2 receptor activation, such as intracellular Ca2+ mobilization.

Clinical uses

Almorexant currently is under development for clinical use in primary insomnia.

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

  1. Almorexant in Adult Subjects With Chronic Primary Insomnia (RESTORA 1). (February 3, 2010). Retrieved on May 6, 2010.